188 related articles for article (PubMed ID: 34364765)
41. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
42. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Jiang Z; Sun Y; Zhang W; Cui C; Yang L; Zhou A
Asia Pac J Clin Oncol; 2020 Jun; 16(3):180-186. PubMed ID: 32077628
[TBL] [Abstract][Full Text] [Related]
43. Oxaliplatin/5-fluorouracil-based adjuvant chemotherapy as a standard of care for colon cancer in clinical practice: Outcomes of the ACCElox registry.
Park YS; Ji J; Zalcberg JR; El-Serafi M; Buzaid A; Ghosn M
Asia Pac J Clin Oncol; 2015 Dec; 11(4):334-42. PubMed ID: 26471890
[TBL] [Abstract][Full Text] [Related]
44. Observational study of adjuvant therapy with capecitabine in colon cancer.
Steffens CC; Tschechne B; Schardt C; Jacobs G; Valdix AR; Schmidt P; Hansen R; Kröning H; Wohlfarth T; Guggenberger D
Curr Med Res Opin; 2015 Apr; 31(4):731-41. PubMed ID: 25651480
[TBL] [Abstract][Full Text] [Related]
45. Retrospective comparison of efficacy and safety of CAPOX and FOLFOX regimens as adjuvant treatment in patients with stage III colon cancer.
Degirmencioglu S; Tanrıverdi O; Demiray AG; Senol H; Dogu GG; Yaren A
J Int Med Res; 2019 Jun; 47(6):2507-2515. PubMed ID: 31099282
[TBL] [Abstract][Full Text] [Related]
46. Clinical impact of baseline renal function on safety and early discontinuation of adjuvant capecitabine plus oxaliplatin in elderly patients with resected colon cancer: a multicenter post-marketing surveillance study.
Yamazaki K; Matsumoto S; Imamura CK; Yamagiwa C; Shimizu A; Yoshino T
Jpn J Clin Oncol; 2020 Feb; 50(2):122-128. PubMed ID: 31665356
[TBL] [Abstract][Full Text] [Related]
47. Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain.
Vieitez JM; García-Carbonero R; Aparicio J; Feliu J; González-Flores E; Grande E; Pérez-Hoyos T; Salud A; Torres E; Valero M; Valladares-Ayerbes M; Díaz-Rubio E
Clin Transl Oncol; 2011 Nov; 13(11):798-804. PubMed ID: 22082644
[TBL] [Abstract][Full Text] [Related]
48. Adjuvant chemotherapy in stage III colon cancer: guideline implementation, patterns of use and outcomes in daily practice in The Netherlands.
van Gils CW; Koopman M; Mol L; Redekop WK; Uyl-de Groot CA; Punt CJ
Acta Oncol; 2012 Jan; 51(1):57-64. PubMed ID: 22122695
[TBL] [Abstract][Full Text] [Related]
49. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
[TBL] [Abstract][Full Text] [Related]
50. Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70.
Lu CS; Chang PY; Chen YG; Chen JH; Wu YY; Ho CL
PLoS One; 2015; 10(9):e0138632. PubMed ID: 26382962
[TBL] [Abstract][Full Text] [Related]
51. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
[TBL] [Abstract][Full Text] [Related]
52. Recurrence-free and overall survival among elderly stage III colon cancer patients treated with CAPOX or capecitabine monotherapy.
van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt JF; Maas HA; Lemmens VE
Int J Cancer; 2017 Jan; 140(1):224-233. PubMed ID: 27615021
[TBL] [Abstract][Full Text] [Related]
53. [Clinical observation of XELOX (Capecitabine puls Oxaliplatin): an adjuvant chemotherapy regimen used in stage III colorectal cancer].
Diao C; Cheng RC; Zhang JM; Wei XP; Su YJ; Liu QY; Xu JB
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):147-50. PubMed ID: 18646702
[TBL] [Abstract][Full Text] [Related]
54. Effect of delay in adjuvant oxaliplatin-based chemotherapy for stage III colon cancer.
Peixoto RD; Kumar A; Speers C; Renouf D; Kennecke HF; Lim HJ; Cheung WY; Melosky B; Gill S
Clin Colorectal Cancer; 2015 Mar; 14(1):25-30. PubMed ID: 25465343
[TBL] [Abstract][Full Text] [Related]
55. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study).
Nakayama G; Takano N; Taniguchi H; Ishigure K; Yokoyama H; Teramoto H; Hashimoto R; Sakai M; Ishiyama A; Kinoshita T; Hayashi N; Nakamura M; Hattori N; Sato Y; Umeda S; Uehara K; Aiba T; Sonohara F; Hayashi M; Kanda M; Kobayashi D; Tanaka C; Yamada S; Koike M; Fujiwara M; Murotani K; Ando M; Ando Y; Muro K; Kodera Y
Eur J Cancer; 2021 Feb; 144():61-71. PubMed ID: 33340853
[TBL] [Abstract][Full Text] [Related]
56. The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study.
Atci MM; Akagunduz B; Demir M; Arikan R; Ay S; Ozer M; Ayhan M; Cil I; Demir N; Ozyurt N; Karakaya G; Cevik GT; Onder AH; Selvi O; Sakin A
J Chemother; 2023 Feb; 35(1):19-28. PubMed ID: 35174772
[TBL] [Abstract][Full Text] [Related]
57. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
[TBL] [Abstract][Full Text] [Related]
58. A Feasibility Study of Capecitabine and Oxaliplatin for Patients with Stage II/III Colon Cancer -ACTOR Study.
Suenaga M; Akiyoshi T; Shinozaki E; Fujimoto Y; Matsusaka S; Konishi T; Nagayama S; Fukunaga Y; Kawakami K; Yokokawa T; Sugisaki T; Ueno M; Yamaguchi T
Anticancer Res; 2018 Mar; 38(3):1741-1747. PubMed ID: 29491111
[TBL] [Abstract][Full Text] [Related]
59. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
André T; Boni C; Navarro M; Tabernero J; Hickish T; Topham C; Bonetti A; Clingan P; Bridgewater J; Rivera F; de Gramont A
J Clin Oncol; 2009 Jul; 27(19):3109-16. PubMed ID: 19451431
[TBL] [Abstract][Full Text] [Related]
60. Adjuvant Chemotherapy for Stage II and III Colon Cancer Following Complete Resection: A Cancer Care Ontario Systematic Review.
Meyers BM; Cosby R; Quereshy F; Jonker D
Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):459-465. PubMed ID: 28341242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
